Two Sigma Advisers’s Poseida Therapeutics, Inc. Common Stock PSTX Stock Holding History

Two Sigma Advisers’s Portfolio PSTX Stock Details PSTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-37,400	Closed	-$107K	–	2583
2024 Q3	$107K	Buy	+37,400	New	+$116K	﹤0.01%	2161
2023 Q3	–	Sell	-191,800	Closed	-$338K	–	2617
2023 Q2	$338K	Buy	191,800 +102,600	+115%	+$262K	﹤0.01%	1948
2023 Q1	$275K	Buy	+89,200	New	+$535K	﹤0.01%	2169

Other funds holding PSTX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

PCM

Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Nomura Holdings Tokyo, Japan $37.7B AUM 34.44% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

AAM

Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return

BCM

Boxer Capital Management San Diego, California $762M AUM 1,125.36% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

ACM

Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return

Two Sigma Advisers's PSTX Position: Q4 2024 in Review

Two Sigma Advisers sold out of Poseida Therapeutics, Inc. Common Stock (PSTX) in Q4 2024, closing a stake of 37,400 shares — an estimated $107K sold.

Two Sigma Advisers first reported a position in PSTX in Q1 2023 and held it in 3 quarters. The position peaked at $338K in Q2 2023. 115 funds tracked by Wall St. Rank hold PSTX as of Q4 2024.

Two Sigma Advisers reported no remaining Poseida Therapeutics, Inc. Common Stock position as of Q4 2024 after selling out during the quarter.
Two Sigma Advisers sold 37,400 Poseida Therapeutics, Inc. Common Stock shares in Q4 2024, an estimated $107K.
Two Sigma Advisers first reported a position in Poseida Therapeutics, Inc. Common Stock in Q1 2023 and held it in 3 quarters.
Two Sigma Advisers's Poseida Therapeutics, Inc. Common Stock position peaked at $338K in Q2 2023.
115 funds tracked by Wall St. Rank held Poseida Therapeutics, Inc. Common Stock as of Q4 2024.

Based on Two Sigma Advisers's 13F filing for Q4 2024, filed 14 Feb 2025.